Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olinvacimab + Pembrolizumab in metastatic triple-negative breast cancer
NCT04986852Phase 2Terminated
- Sponsor
- PharmAbcine
- Start
- Sep 2021
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olinvacimab in triple-negative breast cancer (TNBC), sponsored by PharmAbcine. Primary endpoint: Objective Response Rate at 24 months. Started Sep 2021; status: terminated.
02
Drugs
olinvacimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04986852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04986852.